| Zentalis Upsizes IPO, Raising $165M for Cancer Drug Clinical Trials | Frank Vinluan | 04/03/20 | New York |
| Bio Roundup: Biotech Billions, COVID-19 R&D, Zolgensma’s Path & More | Sarah de Crescenzo | 04/03/20 | National |
| Celularity to Test Natural Killer Cell Therapy for Cancer Against COVID | Sarah de Crescenzo | 04/02/20 | National |
| Aspen Neuro Adds $70M to Test Parkinson’s Cell Therapy in the Clinic | Sarah de Crescenzo | 04/01/20 | San Diego |
| Axsome Plans to Try Again After Failure in Treatment-Resistant Depression | Frank Vinluan | 03/30/20 | New York |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| FDA Approves Bristol Myers MS Drug, But Pandemic Will Delay Launch | Frank Vinluan | 03/26/20 | New York |
| Oncology Needs Combo Therapies & More Data Analysis, Says Bio-Europe Spring Panel | Sarah de Crescenzo | 03/26/20 | Boston |
| Kallyope Gains $112M to Move “Gut-Brain Axis” Programs to the Clinic | Sarah de Crescenzo | 03/25/20 | New York |
| Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing | Brenda Sandburg | 03/24/20 | National |
| Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown | Sarah de Crescenzo | 03/23/20 | National |
| FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes | Frank Vinluan | 03/23/20 | Europe |
| Bio Roundup: Coronavirus Diagnostics, Therapeutics, Vaccines & More | Sarah de Crescenzo | 03/20/20 | National |
| As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future | Editors | 03/19/20 | Boston |
| Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More | Frank Vinluan | 03/13/20 | National |
| Kymera Closes $102M Round to Bring Protein-Busting Drugs to the Clinic | Frank Vinluan | 03/12/20 | Boston |
| Cushing’s Disease Drug That Novartis Sold to Recordati Nabs FDA Nod | Frank Vinluan | 03/09/20 | Europe |
| Zentalis Leads a Trio of Biotechs Charting a Course for Wall Street | Frank Vinluan | 03/09/20 | New York |
| Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More | Sarah de Crescenzo | 03/06/20 | National |
| Melinta’s Chapter 11 Auction Draws No Bids, Deerfield to Get Assets | Frank Vinluan | 03/04/20 | New York |
| National Xconomy Awards Now Accepting Nominations for the Best in Biotech | Editors | 03/03/20 | National |
| Xilio Unveils New Name, $100M to Bring Targeted Cancer Drugs to Clinic | Frank Vinluan | 03/02/20 | Boston |
| Bio Roundup: COVID-19 Trials, Esperion’s Approvals, NASH News & More | Frank Vinluan | 02/28/20 | National |
| Passage Bio’s IPO Raises $216M to Fund Gene Therapy Studies | Sarah de Crescenzo | 02/28/20 | National |
| Biohaven’s Migraine Pill Is the Latest CGRP Drug to Win the FDA’s OK | Frank Vinluan | 02/27/20 | New York |
| Esperion’s FDA-Approved Cholesterol Drug Priced Even Lower Than Expected | Frank Vinluan | 02/24/20 | Detroit Ann Arbor |
| NGM Bio’s NASH Drug Shows Promise, Shares Rise on Early Phase 2 Data | Sarah de Crescenzo | 02/24/20 | San Francisco |
| Lundbeck’s Alder Bio Bet Pays Off With FDA Approval of Migraine Drug | Frank Vinluan | 02/23/20 | National |
| Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More | Sarah de Crescenzo | 02/21/20 | National |
| Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test | Sarah de Crescenzo | 02/18/20 | San Francisco |
